Combined with our cell-communication data, this study suggests that applying medications such as JAK inhibitors and IL-6 inhibitors may be most effective in the early stages of LS—when macrophages (indirectly T cells) are influencing fibroblasts to activate inflammatory and fibrotic gene expression—potentially inhibiting a large amount of collagen deposition and fibrosis in the dermis and deeper connective tissue, highly attenuating the impact of the disease, and improving the quality of life in patients with LS. The gene discussed is IL6; the disease is Leigh syndrome.